Variant Gene Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1695
rs1695
Malignant neoplasm of colon and/or rectum
0.080 GeneticVariation BEFREE GSTP1 Ile105Val polymorphism and colorectal cancer risk: an updated analysis. 23811488

2013

dbSNP: rs1695
rs1695
Malignant neoplasm of colon and/or rectum
0.080 GeneticVariation BEFREE In conclusion, the GSTP1 Ile105Val polymorphism is unlikely to affect the risk of colorectal cancer. 22938488

2012

dbSNP: rs1695
rs1695
Malignant neoplasm of colon and/or rectum
0.080 GeneticVariation BEFREE GSTP1 I105V polymorphism and susceptibility to colorectal cancer in Kashmiri population. 21711092

2012

dbSNP: rs1695
rs1695
Malignant neoplasm of colon and/or rectum
0.080 GeneticVariation BEFREE Controversy exists about whether GST polymorphisms (GSTM1 null/present genotype, GSTT1 null/present genotype, GSTP1 Ile105Val and GSTA1 *A/*B) represent risk factors for colorectal cancer. 20207535

2010

dbSNP: rs1695
rs1695
Malignant neoplasm of colon and/or rectum
0.080 GeneticVariation BEFREE To determine whether genetic polymorphisms of GSTP1 Ile105Val (A-->G) predict chemosensitivity and clinical outcome in patients with advanced colorectal cancer, treated by 5-FU/oxaliplatin-based chemotherapy. 20047135

2009

dbSNP: rs1695
rs1695
Malignant neoplasm of colon and/or rectum
0.080 GeneticVariation BEFREE In conclusion, the meta-analysis suggests that the GSTP1 Ile105Val polymorphism is unlikely to increase considerably the risk of sporadic colorectal cancer, and it should be confirmed in further studies. 19643601

2009

dbSNP: rs1695
rs1695
Malignant neoplasm of colon and/or rectum
0.080 GeneticVariation BEFREE GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. 18797455

2008

dbSNP: rs1695
rs1695
Malignant neoplasm of colon and/or rectum
0.080 GeneticVariation BEFREE The GSTP1 Ile(105)Val polymorphism is associated in a dose-dependent fashion with increased survival of patients with advanced colorectal cancer receiving 5-FU/oxaliplatin chemotherapy. 12072547

2002